Efficacy and safety of cabozantinib (CABO) for advanced Grade 3 (G3) neuroendocrine tumours (NETs) after progression on prior therapy: Subgroup analysis of the phase III CABINET trial (Alliance A021602) Meeting Abstract


Authors: Strosberg, J.; Zemla, T.; Geyer, S.; Pulsipher, S.; Behr, S.; Raj, N.; Vijayvergia, N.; Dasari, A.; Meyerhardt, J.; Wolin, E.; Halfdanarson, T.; Chan, J. A.
Abstract Title: Efficacy and safety of cabozantinib (CABO) for advanced Grade 3 (G3) neuroendocrine tumours (NETs) after progression on prior therapy: Subgroup analysis of the phase III CABINET trial (Alliance A021602)
Meeting Title: 22nd Annual European Neuroendocrine Tumor Society (ENETS) Conference
Keywords: cabozantinib; pancreatic neuroendocrine tumour; grade 3 neuroendocrine tumour; extra-pancreatic neuroendocrine tumour
Journal Title: Journal of Neuroendocrinology
Volume: 37
Issue: Suppl. 1
Meeting Dates: 2025 Mar 5-7
Meeting Location: Krakow, Poland
ISSN: 0953-8194
Publisher: Wiley Blackwell  
Date Published: 2025-03-01
Start Page: e70018
Language: English
ACCESSION: WOS:001535097100267
PROVIDER: wos
DOI: 10.1111/jne.70018
PUBMED: 40040252
Notes: Meeting Abstract: E48 -- Located on page 205 of the electronic document -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Nitya Prabhakar Raj
    114 Raj